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1. Introduction 
Experimental and clinical trials of probiotic use as capable preventive and therapeutic 
strategy in different diseases varying from allergic to autoimmune disease have recently 
reported. Probiotics are used in allergic disease, which have shown to be beneficial in some 
patients with atopic dermatitis and allergic rhinitis [1]. Based on the hygiene hypothesis, it 
has been theorized that changes in human intestinal microflora in developed societies cause 
an increase in the prevalence of autoimmune disease (AD) besides allergies [2]. Regulation 
of intestinal microflora composition by probiotics may offer the possibility to influence the 
development of mucosal/systemic immunity as well as ADs. In this article we will consider 
the etiology of AD and its relation to gut and environmental microbiota (hygiene) before 
discussing the mechanisms of probiotic effect and the beneficial effects that they may confer 
to individuals with AD.  
2. Brief pathophysiology of AD: What causes an AD? 
The immune system normally acts to ensure tolerance to ‘self’, but a breakdown in the 
tolerogenic pathways has been hypothesized to lead to AD that may result from loss of 
tolerance to self antigens in general. A breakdown in the tolerogenic pathways can also lead 
to other so-called inflammatory diseases e.g. atopic and inflammatory bowel disease (IBD). 
Allergic disease may result from loss of tolerance to food and environmental antigens; IBD 
may result from loss of tolerance to commensal bacteria within the intestinal tract. The main 
characteristics of IBD and AD are tissue destruction and functional impairment as a 
consequence of immunologically mediated mechanisms which are principally the same as 
those functioning against dangerous (pathogenic) infections. In case of ADs, a major effort 
was done in understanding pathogenetic mechanisms leading to the loss of tolerance to self 
components (autoantigens). Despite the fact that target antigens and the genetic basis of 
several ADs are now better understood, the initial events leading to a loss of tolerance 
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towards self components remain unknown. One of the most attractive explanations for 
autoimmune phenomena has always centered on various infections as possible natural 
events capable of initiating the process in genetically predisposed individuals. 
The most accepted conventional hypothesis explaining how infectious components cause 
autoimmunity is based on the concept of cross-reactivity, “molecular mimicry”. This 
hypothesis assumes a similarity between the epitopes of an autoantigen present in the 
afflicted organism and the epitopes in the environmental antigen. The latter may consist of a 
microorganism or another external antigen that causes the autoimmune response. The other 
hypotheses in the AD pathogenesis such as hygiene-old friends- hypothesis, bystander 
immunoregulation and T regulatory cell (Treg) defects are briefly discussed below as well.  
Because of our long association with environmental organisms (old friends), they are 
recognized by the innate immune system as harmless or, in the case of some helminths, 
treated as ‘‘friends’’ because a response would merely lead to immunopathology [2]. 
Therefore, rather than priming aggressive immune responses, these organisms prime 
immunoregulation. They do it by inducing an unusual pattern of maturation of dendritic 
cells (DC) such that these retain the ability to drive Treg. Toll-like receptor 2 (TLR2) may be 
involved for helminths and TLR9 for lactobacilli. It is interesting that polymorphisms of 
NOD2 (an intracellular receptor for bacterial peptidoglycan) are linked to increased 
susceptibility to both Crohn’s disease and asthma [3]. Thus an extension of the ‘‘hygiene’’ 
mechanism suggests that in an environment that less actively primes Treg activity, 
immunoregulatory disorders will occur first in those individuals whose innate immune 
systems are least efficient at driving Treg. 
The increased regulatory dendritic cells (DCreg) and Treg induced by ‘‘old friends’’ then 
lead to two immunoregulatory mechanisms mediated in part by release of IL-10 and TGF-ǃ. 
Firstly, continuing exposure to ‘‘old friends’’ will cause continuous background activation of 
Treg specific for the ‘‘old friends’’ themselves, resulting in a constant background of 
“bystander suppression” [4]. This mechanism has been demonstrated in a model of colitis. 
Secondly, DCreg inevitably sample self and gut contents and so induce Treg specific for the 
target antigens of the groups of chronic inflammatory disorder. These mechanisms may be 
aborted when there are legitimate ‘‘danger’’ signals. For example, Treg function can be 
turned off by appropriate ‘‘danger signals’’ in vitro [5]. 
The unifying hypothesis explaining the simultaneous increase in T helper type 2 (Th2)-
mediated allergies and Th1-mediated autoimmunity is that modern living conditions can 
lead to defective maturation of Treg and regulatory antigen presenting cell or DCreg [6]. 
Therefore, rather than Th1/Th2 balance, the crucial factor is likely to be the effector T 
cells/Treg balance. Thus diminished immunoregulation can lead to inappropriate immune 
responses to allergens, gut contents, or self. In the absence of optimal levels of 
immunoregulation, the individual may develop a Th1-/Th2-mediated inflammatory 
disorder, depending on his/her own particular Th1/Th2 bias, immunological history, and 
genetic background. Evidence to confirm this hypothesis has come from studies of allergic 
disorders, MS and autoimmune polyglandular syndromes [6].  
3. Any role for hygiene (environmental microbiota) in AD development?  
According to the old 'hygiene (old friends) hypothesis', the decreasing incidence of 
infections in developed and developing countries is at the origin of the increasing incidence 
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of allergic diseases [7]. New practices, introduced as a result of industrialization, such as 
childbirth by surgical delivery, ingestion of pasteurized food, cleaner homes, and 
indiscriminate use of antibiotics and so on, have led in recent years to the replacement of 
probiotics by other microorganisms that are not as well adapted to the microenvironments 
of the human body. The hygiene hypothesis is based upon epidemiological data, 
particularly migration studies, showing that subjects migrating from a low-incidence of 
infections to a high-incidence country acquire the allergic and immune disorders with a 
high incidence at the first generation as well. Therefore, it was possible to extend the old 
hypothesis from the field of allergy, where it was formulated, to those of ADs such as T1D 
or multiple sclerosis (MS) [7,8]. However, some data and others showing a correlation 
between high AD incidence and high socio-economic level do not prove a causal link 
between infections and immune disorders. Part of the increased incidence of these diseases 
may be somewhat attributed to better diagnosis or improved access to medical facilities in 
economically developed countries. However, this cannot explain the marked increase in 
immunological disorder prevalence that has occurred over such a short period of time in 
those countries, particularly for diseases which can be diagnosed easily, such as T1D or MS.  
Proof of principle of the hygiene hypothesis is suported by animal models and to a lesser 
degree by intervention trials in humans. The incidence of spontaneous T1D is directly 
correlated with the sanitary conditions of the animal facilities, for both the non-obese diabetic 
(NOD) mouse and the bio-breeding diabetes-prone (BBDP) rat: the lower the infectious 
burden, the higher the disease incidence [8,9,10]. Diabetes has a very low incidence and may 
even be absent in NOD mice bred in ‘conventional’ facilities, whereas the incidence is close to 
100% in female mice bred in specific pathogen-free conditions [11]. Furthermore, BBDP rats 
subject to Cesarean derivation have been noted to develop accelerated disease due to lack of 
contamination with microbiota in birth canal [12]. Taken together, these data open new 
therapeutic perspectives in the prevention of allergic and ADs.  
4 Intestinal microbiota and their role in ADs? 
Based on hygiene hypothesis, the sudden change in human intestinal microflora may 
importantly contribute to the rise in the incidence of ADs, observed in the last half a 20th 
century [7]. More than 17 bacterial families encompassing 500 different microbial species can 
be found in human adults. These commensal bacteria regulate a myriad of host processes 
and provide several nutrients to their host and their symbionts within the microbial 
community. In healthy individuals these relationships are thought to occur in equilibrium. 
However, disruption of this equilibrium may contribute to a variety of conditions including 
AD, IBD and atopic disease [13]. This connection is gaining credibility as associations 
between gut microbiota and either the risk for or presence of a variety of specific human 
diseases is demonstrated.  
Accordingly, the pathogenesis of ADs has been recently thought to involve an interaction 
between genetically determined host susceptibility, the enteric microbiota and dysregulated 
immune response. Interactions between the intestinal environment, barrier function, and 
immune system have been shown to have a major impact in the rate of autoimmunity 
development. Disruption of intestinal barrier function and aberrant mucosal immune 
activation has been implicated in a variety of diseases within and outside of the 
gastrointestinal tract [2,9]. The penetration of gut bacterial antigens into lymphoid tissues is 
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one of the suggested initial factors leading to a loss of tolerance towards self components in 
genetically predisposed individuals. With this model in mind, recent studies have shown a 
link between diet, composition of intestinal microbiota, and pathogenesis of ADs. 
Furthermore, this new paradigm subverts traditional theories underlying autoimmunity 
development, which are mainly based on molecular mimicry, and suggests that the 
autoimmune process can be arrested if the interplay between genes and environmental 
triggers is prevented by re-establishing intestinal barrier function [14]. 
A hypothesis previously has been proposed involving a trio of interacting factors that may 
create a ‘‘perfect environment ’’ for ADs such as type 1 diabetes (T1D) development. These 
factors include (i) an aberrant intestinal microbiota, (ii) a ‘leaky’ intestinal mucosal barrier, 
and (iii) altered intestinal immune responsiveness [15]. In support of this model, modulation 
of T1D pathogenesis in animal models has proved successful through early intervention 
with a variety of dietary alterations. Indeed, the administration of a hydrolyzed casein diet 
or the administration of antibiotics has strengthened the hypothesis that an aberrant 
microbiota could accelerate disease development. More importantly, this is not a 
phenomenon that occurs only in rodent models of diabetes, as very recent studies have 
noted that humans with a propensity to develop T1D as well as other ADs possess an 
abnormal intestinal barrier; the so called “leaky gut” [8,14]. Together with the gut-associated 
lymphoid tissue and the neuroendocrine network, the intestinal epithelial barrier, with its 
intercellular tight junctions, controls the equilibrium between tolerance and immunity to 
nonself-antigens. Other modulators of tight junction proteins such as certain probiotics may 
also play a role in modulation of “intestinal leakiness” [8,9,13,15]. 
5. What are probiotics?  
Probiotics are usually isolated from the commensal microflora that inhabits the skin and 
mucosas. And they represent the species of viable microorganisms (bacteria or yeasts) that 
have a clear beneficial effect on the health of the host thru establishing a true symbiotic 
relationship with humans for the longest time. Probiotic is derived from the Greek word 
meaning “supporting or favoring life”. The works of Metchnikoff and Tissier were the first 
to make scientific suggestions about the probiotic use of bacteria, even if the word 
"probiotic" was not coined until 1960, to name substances produced by microorganisms 
which promoted the growth of other microorganisms [16].  
Probiotics are first described as selective nonpathogenic living microorganisms or 
components of bacteria in food supplements, including some commensal bacterial flora, 
which have beneficial effects on host health and disease prevention and/or treatment [17]. 
However, experts have debated how to define probiotics. One widely used definition, 
developed by the World Health Organization and the Food and Agriculture Organization of 
the United Nations, is that probiotics are "live microorganisms, which, when administered 
in adequate amounts, confer a health benefit on the host." Probiotics are also defined as 
‘mono- or mixed cultures of live microorganisms which, when applied to animal or man, 
beneficially affect the host by improving the properties of the indigenous microflora’ [16].   
A probiotic bacterium is required to fulfill certain criteria to be of benefit [1]. These include 
being of human origin and having generally regarded as safe status, acid and bile stability, 
adherence to intestinal cells, persistence for some time in the gut, ability to produce 
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antimicrobial substances, antagonism against pathogenic bacteria, and ability to modulate 
the immune response. Probiotic activity has been found to be associated with Lactobacilli, 
Lactococci, Bifidobacteria (longum, infantis), Streptococcus (thermophilus), Enterococcus 
(faecium), nonpathogenic E. coli (Nissle 1917), Bacillus coagulans and Saccharomyces strains 
(boulardii and cerevisiae) [1,17]. The most popular lactic acid bacteria are members of the 
genera Lactobacilli and Lactococci, which have a long history of safe use. Lctb acidophilus is 
the most well-known probiotic and one of the most important for the health of the small 
intestine. Other examples of probiotics are Lctb rhamnosus GG (LGG), Lctb gasseri, Lctb 
fermentum, Lctb salivarius, Bfdbm bifidum and Streptococcus strains include cremoris, 
faecium and infantis. 
The number of commercially available products that are supplemented with probiotics is 
rising. Dairy products that contain probiotics are sold in every supermarket and probiotic food 
supplements (for example; capsules, tablets, and powders) can be purchased in pharmacies or 
via the internet. For infants, infant formulas containing probiotics are also currently available. 
Live probiotic cultures are available in fermented dairy products and probiotic fortified foods. 
Examples of foods containing live probiotics are yoğurt, fermented and unfermented milk, 
miso, tempeh, and some juices and soy beverages. However, tablets, capsules, powders and 
sachets containing the bacteria in freeze dried form are also available. 
6. A cultural product related to probiotics: Yogurt (Yoğurt)  
Increasing interest has also been paid to the beneficial functions of Lactobacilli in addition to 
their importance in the preparation process of fermented foods such as yoğurt and cheese. 
Here, the reason for selecting yoğurt as a probiotic food was several-fold. It can be produced 
in a sustainable manner locally and therefore doesn't rely on importation, and it provides 
nutrition and is an excellent carrier for probiotic organisms.  
Fermented foods, particularly dairy products like yoğurt, have been consumed for centuries 
in some cultures including Turkish. A similar health effect is also observed for lactose 
fermenting starter bacteria such as Lctb delbrueckii ssp. bulgaricus and Streptococcus 
thermophilus in fermented milk products like yoğurt. However, these traditional starters 
are not considered probiotics by some researchers since they lack the ability to proliferate in 
the intestine [16]. Therefore probiotic yoğurt including different probiotic strains 
(lactobacilli and/or bifidobacteria) than standard one has been produced and become 
popular in recent literature. Probiotic yoğurt includes a probiotic strain or multistrain 
probiotics that has been shown to have beneficial effects on the health of the host with 
HIV/AIDS and diarrhea [18]. Traditional yoğurt was compared in a study with probiotic 
yoğurt in non-inflammatory acute gastroenteritis. Acute non-inflammatory gastroenteritis 
improvement is accelerated by probiotic yoğurt consumption [19]. Probiotic yoğurt intake 
was associated with significant anti-inflammatory effects that paralleled the expansion of 
peripheral pool of putative T(reg) cells in IBD patients and with few effects in controls [20]. 
Yoğurt contains viable bacteria culture including Streptococcus thermophilus and Lctb 
delbrueckii sp. bulgaricus [1]. Although these cultures clearly fulfill the current concept of 
probiotics, only a small number of these bacteria have been studied. Yet some specifically 
have been shown to have a probiotic effect [1,21,22]. Health effects of traditional (standard) 
yoğurt will not be reviewed in detail here; several reviews have already been published on 
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this topic [1,16,21]. Yoğurt has been shown to be successful for reducing the duration of 
symptoms in acute non-bloody diarrhea in 6-24-month-old hospitalized infants [23]. Yoğurt 
feeding was associated with a clinically relevant decrease in stool frequency and duration of 
diarrhea in children who have reducing sugars in stools [24]. Positive changes in lipid 
profile were observed in both yoğurt groups [25].  
Although there is well-known assumption of longer human life in the cultures consuming 
frequently yoğurt, the neat probiotic effect of yoğurt on the frequency of ADs is unknown.  
7. Can probiotics really prevent and/or treat any type of ADs? 
The new version of 'hygiene hypothesis' proposes that reduced exposure to environmental 
and/or enteric stimuli, including microbes, underlies the rising incidence of childhood ADs 
[7,15,26]. This hypothesis is supported by data that highlight the importance of infant 
exposure to environmental microbes for appropriate development of the immune system. 
This might explain the observation that administration of microbes or their components 
inhibits AD in animals such as T1D, as mentioned above [2,13-15]. These findings raise the 
possibility of using live, nonpathogenic microbes (for example, probiotics) or microbial 
components to modulate or’re-educate' the immune system.  
For some time now, microbial agents have been implicated in the etiology of ADs, including 
insulin dependent diabetes mellitus (T1D). Recent studies, however, have revealed that 
exposure of genetically diabetes-susceptible animals to certain microbes or microbial agents 
at an early age prevent the induction and progression of disease. This suggests that 
microbes may act to modulate the immunological status or immune repertoire of an 
individual genetically programmed for T1D away from an autoimmune response [27]. 
Immunization with microbial agents at an early age may offer an important new direction 
for the immunotherapy of T1D [10,28]. The protective effect of a probiotic and a bacterial 
extract was reported on the onset of diabetes in NOD mice.  
Similarly, there is an increasing amount of data showing that intestinal microbiota changes 
could contribute to the modulation of immune disorders but evidence is still slim, except in 
IBD. The case of probiotics in IBD is more complex because of the possible local anti-
inflammatory effect, which could explain the relief of symptoms without changes in disease 
progression, as implicated in the hygiene hypothesis. Following a number of uncontrolled 
studies in a small cohort of 14 pediatric patients with newly diagnosed ulcerative colitis 
(UC), probiotic treatment induced a significant rate of remission compared to the control 
group and a lower relapse rate [29].  
Supposed Mechanisms of Probiotics` Effects in the Prevention/Treatment of ADs 
Some supposed mechanisms of probiotics` effects in the development of autoimmunity 
defined in the recent literature are discussed below (as summarized and shown in figure 1). 
1. Immunoregulation by TGF-ǃ-bearing Treg cells 
CD4+/CD25+ - Tregs have shown to be pivotal players in the maintenance of immune 
tolerance. Their role in the prevention of autoimmunity in animal models and evidence for 
disturbed or dysfunction of Tregs have also been observed in patients with different ADs, 
including MS [6]. Recent studies provided evidence that one effect of probiotics may involve 
induction of differentiation of IL-10-dependent, TGF-ǃ-bearing Tregs [6]. They also can 
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suppress immune responses distinct from responses against the antigen in question, here 
antigens expressed by infectious agents (a phenomenon called bystander suppression).  
 
Fig. 1. This figure illustrates some supposed mechanism of probiotic effects on the 
development of autoimmunity and autoimmune diseases. Probiotics seem to have a 
regulatory effect on Treg, Th1, Th17, intestinal cells and splenocytes. 
2. Development of tolerogenic DCs 
Lctb reuteri / casei have been also shown to prime monocyte-derived DCs through the C-
type lectin DC-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) 
to drive the development of Tregs [30].  These Tregs produce increased levels of IL-10 and 
are capable of inhibiting the proliferation of bystander T-cells. This study suggests that the 
targeting of DC-SIGN by certain probiotic bacteria might explain their beneficial effect in the 
treatment of a number of inflammatory diseases, including AD [1].  
3. Reducing proinflammatory cytokines through Th17 cells 
Th17 has been also shown as pathogenic cells in some ADs such as experimental 
autoimmune encephalomyelitis (EAE) and arthritis [31]. Suppression of this newly 
discovered subset of T cells by probiotics might explain effects observed in different 
experimental models that all involve inflammatory responses, i.e. colitis. For instance; Lctb 
casei suppressed experimental arthritis by reducing proinflammatory cytokines released 
from Th17 cells.  
4. Stimulating Th1 cells 
Although there are still some studies showing no significant effects of probiotics on either 
Th1/Th2 cell responses, certain strains of Lctb and Bfdbm modulate the production of 
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cytokines, and may divert the immune system in a regulatory or tolerant mode. Changes in 
cytokine profile induced by probiotics may be probiotic strain- or site-specific and 
dependent on the experimental system used. For instance, Lctb reuteri induced 
proinflammatory and Th1 cytokines; and Bfdbm bifidum/infantis and Lctb lactis reduced 
Th2 cytokines and acted as potent inducers of IL-10 production [32].  
5. Probiotic regulation in intestinal epithelium and upregulation of host immune 
responses to defend against infection 
Probiotics compete with non-commensal bacteria and eliminate them by secreting 
antimicrobial products, increase the production of antibodies and macrophage activity and 
contribute to the appropriate host nutrition by producing some vitamins and by breaking 
down undigested molecules. These characteristics argue in favor of a symbiotic relationship 
between humans and probiotics [1].  Probiotic administration in humans and animals has 
also been shown to be beneficial in the treatment and prevention of intestinal infections and 
to reduce mucosal inflammation. Their ability to deviate tissue cytokine secretion from a 
pro-inflammatory to an anti-inflammatory profile has been specifically described. This effect 
probably results from the ability of probiotics to adhere to mucosal surfaces and inhibit the 
attachment of other pathogenic bacteria, to secrete factors that enhance barrier integrity, and 
to modulate cells of the immune system [33].  
6. Anti-inflammatory effect of probiotics 
The anti-inflammatory effect of probiotics has been attributed to increased production of IL-
10 by immune cells in the lamina propria, Peyer’s patches and the spleen of treated animals 
[34]. Moreover, a decrease in the secretion of pro-inflammatory cytokines, IFN-Ǆ, TNF-ǂ and 
IL-12 has been demonstrated [33].  
7. Maturing gut barrier 
Recent data indicate that commensal intestinal microbiota represents a major modulator of 
intestinal homeostasis. Dysregulation of the symbiotic interaction between intestinal 
microbiota and the mucosa may result in a pathological condition with potential clinical 
repercussions. For instance, it is shown that mice reared in germ-free conditions have an 
underdeveloped immune system and have no oral tolerance. In contrast, pathogen-free mice 
are capable of reconstituting the bacterial flora with Bfdbm and tolerance development. In 
addition to providing maturational signals for the gut-associated lymphoid tissue, 
probiotics balance the generation of pro- and anti-inflammatory cytokines in the gut. After 
probiotic consumption, decrease in fecal ǂ-1 antitrypsin, serum TNF-ǂ, and changes in TGF-
ǃ and other cytokines point to down-regulation of inflammatory mediators [33]. 
Furthermore, probiotic bacteria may counteract the inflammatory process by stabilizing the 
gut microbial environment and the permeability barrier of the intestine, and by enhancing 
the degradation of enteral antigens and altering their immunogenicity. This gut-stabilizing 
effect of probiotics could be explained by the improvement by probiotics of the 
immunological barrier of the intestine through intestinal IgA responses, specifically [1,35].  
8. Systemic TLR stimulation via non-antigenic ligands 
A number of experiments indicate that infectious agents can promote protection from ADs 
through mechanisms independent of their constitutive antigens, leading to stimulation of 
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non-antigen specific receptors such as TLRs. A family of pattern recognition receptors such 
as TLRs on gut lymphoid and epithelial cells mediates innate immune responses to bacterial 
molecular patterns and, thereby, orchestrates acquired immunity. An observation made for 
TLR-2/-3/-4/-7 and -9 that TLR stimulation could prevent the onset of T1D in NOD mice 
[9,10,36].  
Although the beneficial effects of probiotics on wide variety of diseases have been shown, 
little is known about how probiotics modulate the immune system and autoimmunity 
development. Currently, only limited publications are available mentioning the effects of 
probiotics on ADs in rodent models or human. Therefore, it was important to explore the 
effect of human probiotics in various autoimmune experimental and clinical disease models. 
Here, firstly experimental and later clinical studies of probiotics in different ADs under the 
recent literature gathered from Medline and Pubmed are discussed.  
8. Animal experimental models and human clinical trials describing 
supposed effects of probiotics in ADs 
Benefits of probiotic use in firstly animal experimental and later human clinical models of 
ADs including arthritis, T1D, EAE and IBD will be mentioned correspondingly in this 
assessment. Presumed favorable effects of probiotics in various ADs reviewed in this article 
are also shown in table 1 and 2.  
 
Disease model Probiotics Assessment Outcome Ref. 
Animal Experimental Autoimmune Encephalomyelitis Models  
EAE LcS ↑IL-10, ↑TGF-ǃ ↓disease 
activity 
55,56 
EAE LcS ↑ Th1 cytokines ↑ disease 
activity 
55,56 
EAE Lctb  reuteri ↑ proinflammatory cytokines ↑ disease 
activity 
32,54 
EAE LcS, BbY myelin basic protein 
Ø disease 
activity 
56 
EAE Lctb casei 393 ↑ IL-10, ↑TGF-ǃ ↓disease 
activity 
55,56 
EAE Bfdbm animalis 
↑Tregs, ↓ immune parameters, ↑ body 
weight gain, 
↓disease 
activity 
57 
EAE Lctb casei ↑ immunoregulatory cytokines ↓disease 
activity 
55,56 
EAE Lctb paracasei 
↓ proinflammatory cytokines, ↑ Tregs 
dependent on IL–10 
↓disease 
activity 
55,58 
EAE Lacto-mix ↑ Tregs, ↑IL-4, ↑IL-10, ↑TGF- ǃ1 ↓disease 
activity 
55,58 
Animal Experimental Inflammatory Bowel Disease Models  
DSS colitis VSL#3 inflammation 
↓disease 
activity 
66 
DSS colitis E. coli Nissle 1917 inflammation 
↓disease 
activity 
66 
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Disease model Probiotics Assessment Outcome Ref. 
IL-10-/- mice 
colitis 
Lctb salivarius ↓IFN-Ǆ ↓disease 
activity 
62,63 
IL-10-/- mice 
colitis 
Bfdbm infantis ↓IFN-Ǆ ↓disease 
activity 
62,64 
IL-10-/- mice 
colitis 
Lctb reuteri inflammation 
↓disease 
activity 
61 
IL-10-/- mice 
colitis 
Lctb plantarum ↓IL-12, ↓IFN-Ǆ ↓disease 
activity 
60 
Animal Experimental Diabetes Mellitus Models  
T1D Lctb  casei ↓ ǃ-cell destruction, ↓IFN-Ǆ, ↑IL-2 ↓ disease 
activity 
51,52 
T1D LcS 
↓ ǃ-cell destruction, ↓autoreactive CD8+ 
T-cells 
↓ disease 
activity 
51,52 
T1D VSL#3 
↓ insulitis and ǃ-cell destruction, ↑IL-10, 
↑IFN-Ǆ 
↓ disease 
activity 
50 
T1D Lctb  johnsonii 
modify gut microbiota:↓ pro-
inflammatory cytokine , ↓IFN-Ǆ,     ↓ iNOS 
and ↑Cox2, ↑claudin (the tight junction 
protein) 
↓ disease 
activity 
48,49 
T1D Lctb reuteri modify gut microbiota 
↓ disease 
activity 
51,52 
Animal Experimental Arthritis Models  
CIA LcS 
↓CII-induced IgG2a/2b, ↓IFN-Ǆ 
production by spleen cells 
↓ disease 
activity 
41 
CIA Lctb casei 
↓proinflammatory cytokines, ↓T-cell 
proliferation, ↑IL-10, ↓CII-induced 
IgG2a/2b, ↑Foxp3+/CD4+-T cells 
↓paw swelling, 
↓disease 
activity, 
↓cartilage 
degradation 
40 
CIA Lctb fermentum 
↓proinflammatory cytokines, ↓T -cell 
proliferation, ↓ IL-10 
↓disease 
activity, 
↓cartilage 
degradation 
42 
CIA Lctb delbrueckii 
↓proinflammatory cytokines, ↓T-cell 
proliferation, ↓ IL-10 
↓disease 
activity, 
↓cartilage 
degradation 
42 
AA LGG inflammation 
↓ disease 
activity 
55 
AA 
Enterococcus 
faecium 
disease intensity 
↓ disease 
activity 
38 
CIA Lctb bulgaricus inflammation 
↓ disease 
activity 
42 
Abbreviations: Lctb: lactobacillus; Bfdbm: bifidobacterium; LcS: Lctb casei Shirota; BbY: Bfdbm breve 
strain Yakult; Lacto-mix: Lctb paracasei, Lctb plantarum, Lctb delbrueckii; LGG: Lctb GG; VSL#3: a 
mixture of four species of lactobacilli, three species of bifidobacteria and Streptococcus thermophilus; DSS: 
dextran sulfate sodium colitis; EAE: experimental autoimmune encephalomyelitis; CIA: collagen induced 
arthritis; AA: adjuvant arthritis; T1D: insulin-dependent Diabetes Mellitus; CII: Type II collagen; ↓: 
decreased in severity of disease; ↑: increased in severity of disease; Ø: no effect on severity of disease.  
Table 1. Probiotic effects in animal experimental autoimmune disease models are shown.  
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Disease Probiotics Assessment Outcome Ref. 
Human Clinical Arthritis Trials  
RA LGG 
clinical/biochemical parameters, 
↓proinflammatory cytokines 
↓ disease 
activity 
43,44 
RA 
Bacillus 
coagulans 
inflammation 
↓ disease 
activity 
45 
RA 
Living / vegan 
food 
health assessment questionnaire 
↓ disease 
activity 
46 
Spondyloarthritis Combination clinical/biochemical parameters 
Ø disease 
activity 
47 
Human Clinical T1D Trials  
T1D Various autoantibodies 
Ø disease 
activity 
53 
Human Clinical Inflammatory Bowel Disease Trials  
Pouchitis VSL#3 inflammation 
↓ disease 
activity 
68,70,71 
Pouchitis LGG inflammation 
↓ disease 
activity 
69,72,73 
Active UC 
E. coli Nissle 
1917 
inflammation, induction of 
remission 
↓ disease 
activity 
75,76 
Active UC VSL#3 
inflammation, induction of 
remission 
↓ disease 
activity 
68,70,71 
Active UC BbY endoscopic and histological scores
↓ disease 
activity 
77,78 
Active UC LGG induction of remission 
Ø disease 
activity 
69,72,73 
UC remission VSL#3 maintenance of remission 
↓ disease 
activity 
79 
UC remission LGG maintenance of remission 
Ø disease 
activity 
76,80 
UC remission 
Bfdbm breve / 
bifidum  Lctb 
acidophilus 
maintenance of remission 
↓ disease 
activity 
78 
Active CD LGG inducing remission 
Ø disease 
activity 
81,82 
Active CD 
E. coli Nissle 
1917 
inducing remission 
Ø disease 
activity 
81 
CD remission S. boulardii maintenance of remission 
↓ disease 
activity 
83 
CD remission LGG maintenance of remission 
Ø disease 
activity 
82,84,85 
CD remission Lctb johnsonii
maintaining surgically induced 
remission 
↓ disease 
activity 
86,87 
CD remission VSL#3 
maintaining surgically induced 
remission 
↓ disease 
activity 
88 
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Celiac disease 
Lctb 
sanfranciscensis
proteolytic activity 
↓ disease 
activity 
89 
Celiac disease 
Lctb 
plantarum 
proteolytic activity 
↓ disease 
activity 
89 
Celiac disease VSL#3 proteolytic activity 
↓ disease 
activity 
90 
Celiac disease Bfdbm lactis proteolytic activity 
↓ disease 
activity 
91 
Human Clinical Multiple Sclerosis Trials  
Multiple Sclerosis Various dysbiosis 
↓ disease 
activity 
59 
 
Abbreviations: Bfdbm: bifidobacterium; Lctb: lactobacillus; BbY: Bfdbm breve strain Yakult; LGG: Lctb 
GG; VSL#3: a mixture of four species of lactobacilli, three species of bifidobacteria and Streptococcus 
thermophilus; CD: Crohn`s disease; UC: ulcerative colitis; RA: rheumatoid arthritis; T1D: insulin-
dependent diabetes mellitus; ↓: decreased in severity of disease; ↑: increased in severity of disease; Ø: no 
effect on severity of disease.  
Table 2. Probiotic effects in human clinical autoimmune disease trials are shown.  
8.1 Ia-probiotic effect in animal experimental arthritis models 
Changes in the normal gastrointestinal microflora and dysregulation of the mucosal 
immune response to these pathogens may contribute to the development of ADs such as 
rheumatoid arthritis (RA). This possibility has led investigators to evaluate the efficacy of 
probiotics for alleviating RA symptoms through modulation of the aberrant inflammatory 
autoimmune response. Of particular interest are LAB probiotics and their 
immunomodulating and anti-inflammatory effects, which have been shown to lessen the 
symptoms of arthritis. LAB have been shown to significantly downregulate 
proinflammatory cytokines (eg, IFN-Ǆ, IL-12, TNF-ǂ) without altering regulatory cytokines 
(eg, IL-10, TGF-ǃ) to cause anti-inflammatory effects alleviating RA symptoms [37].  
Adjuvant arthritis (AA) is a classic murine model for RA, which has been considered a 
prototype of Th1 disorders. Feeding dairy products fermented with lactobacilli, especially 
LGG, to rats with AA had a noticeable beneficial effect, surpassing even the effect of oral 
Lctb GG (LGG) alone. There was a statistically significant decrease in inflammation 
histologically over one month in rats fed yoğurt containing LGG compared with rats fed 
plain yoğurt or milk. Ingestion of live or heat-killed human LGG had the same clinical 
beneficial effect. The authors concluded that the LGG, especially in the form of fermented 
yoğurt, apparently exert both preventive and therapeutic effects on the T-cell-dependent 
experimental arthritis [37]. Accordingly, AA rats treated in combination with 
methotrexate and lyophilized probiotic bacteria Enterococcus faecium, enriched with 
organic selenium, had a significantly greater reduction in disease intensity than the 
methotrexate group [38].  
Type II collagen (CII)- induced arthritis (CIA) is considered to be a good model of RA in 
humans and is often used as a system to evaluate antiinflammatory drugs. An earlier study 
found that Lctb casei reduced the incidence and development of CIA in mice in a dose 
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dependent manner. Oral administration of Lctb casei for 12 weeks reduced signs of CIA 
including paw swelling, lymphocyte infiltration into the joint, and degradation of cartilage 
when compared with control animals. Lctb casei administration reduced CII-reactive 
proinflammatory molecules by CD4+-T cells. Lctb casei administration also reduced CII-
reactive Th1-type IgG isotypes IgG2a and IgG2b, while up-regulating immunoregulatory IL-
10 levels. These results suggest that oral administration of Lctb casei suppresses the CII -
reactive effector function of Th1-type cellular and humoral immune responses in arthritic 
inflammation [39]. Furthermore; in another study CII alone or together with Lctb casei was 
orally administered into rats with CIA, and its effects on the clinical and histopathological 
aspects of arthritis were investigated. Coadministration of Lctb casei with CII more 
effectively suppressed clinical symptoms, paw swelling, lymphocyte infiltration and 
destruction of cartilage tissues of experimental arthritis than the rats treated with CII alone. 
The enhanced therapeutic efficacy was associated with an increase in anti-inflammatory 
cytokines while decreasing proinflammatory cytokines. Coadministration of Lctb casei with 
CII more effectively suppressed CII-reactive T cell proliferation and the levels of Th1-type 
IgG isotypes (IgG2a and IgG2b), while up-regulating Foxp3 expression levels and the 
population of Foxp3+/CD4+ -T cells. This study indicates that Lctb casei could potentiate 
antigen-specific oral tolerance and suppress Th1-type immune responses of arthritic 
inflammation [40].  
Also, oral administration of Lctb casei Shirota (LcS) into CII-sensitized DBA/1 mice reduced 
CII-induced IgG2a/2b antibodies in serum and suppressed the CII-induced secretion of 
IFN-Ǆ from splenocytes ex vivo. It has also been shown that LcS prevented the onset of CIA 
in DBA/1 mice [41]. Other studies have reported similar improvements in measures of 
arthritis after administration of Lctb fermentum and Lctb. delbrueckii. Oral intake of skimmed 
milk fermented with Lctb delbrueckii subsp. bulgaricus OLL 1073R-1 prevented CIA in mice. A 
weaker beneficial effect was noted with fresh skimmed milk and with skimmed milk 
fermented with another strain of the Lctb. bulgaricus, OLL 1102 [42].  
8.2 Ib-probiotic effect in human clinical arthritis trials 
A pilot double-blind clinical study evaluated the long-term effects of LGG on symptoms of 
RA. Twenty-one RA patients were randomized to receive 2 capsules of LGG or placebo 
twice daily for 12 months. RA activity was reduced in 71% of patients in the LGG group vs 
30% of patients in the placebo group. Although there were no statistical differences in 
clinical or biochemical parameters, more patients in the LGG group reported a greater 
feeling of well-being [43]. Furthermore, the effects of an orally administered probiotic LGG 
on sulfasalazine metabolism in individuals with RA were studied in a preliminary study. 
Although there were also no statistical significant differences in the activity of RA, more 
subjects in the LGG group reported subjective well being [44]. 
In another pilot study, RA patients who received Bacillus coagulans experienced significant 
improvement in the pain, greater improvement in patient global assessment, patient self-
assessed disability, and reduction in total CRP. Bacillus coagulans is a gram-positive, spore-
forming, aerobic to microaerophilic LAB bacillus that releases anti-inflammatory molecules 
or acts indirectly to eradicate organisms in the gut responsible for the inflammatory immune 
response [45].  
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A change in the fecal microflora was connected with decreasing activity of RA for one year 
intervention with living food. ‘Living food’ is an uncooked vegan diet, which contains no 
animal products, raffinated substances or added salt. The effects of this diet, rich in 
lactobacilli, in RA patients randomized into diet and control groups were tested. The 
intervention group experienced subjective relief of rheumatic symptoms during 
intervention. A return to an omnivorous diet aggravated symptoms. Half of the patients 
experienced adverse effects (nausea, diarrhoea) during the diet and stopped the experiment 
prematurely. Nonetheless there was a decrease in the disease activity with lactobacilli-rich 
and chlorophyll-rich drinks, increase in fibre intake, and no need for gold, methotrexate or 
steroid medication [46].  
In another randomized controlled trial, sixty-three patients with active spondyloarthritis 
(enteropathic peripheral arthropathies) were randomized to oral probiotic (n = 32) or 
placebo (n = 31) for 12 weeks. No significant difference was noted between groups in any of 
the core domains (pain, spinal mobility, patient global, peripheral joint and entheseal scores, 
stiffness, C-reactive protein, and fatigue) [47].  
8.3 IIa-probiotic effect in animal experimental T1D models 
The NOD mouse and BBDP rat develop a spontaneous form of human T1D that mimics 
many features of the human disease, thus representing a model for investigating possible 
therapeutic approaches. A study reported a culture-independent analysis of the bacteria in 
fecal samples collected from BBDP and BioBreeding diabetes resistant (BBDR) rats. Two 
genera of bacteria, Lctb and Bfdbm, emerged as dominant groups negatively correlated with 
the onset of T1D. Further analysis of the Lctb population within these groups established 
that Lctb strains with cinnamoyl esterase activity, Lctb johnsonii N6.2 and Lctb reuteri TD1 
were negatively correlated with T1D development [48]. Taken collectively, these data 
suggest that the gut and the gut microbiota are potential agents of influence in T1D 
development. Consistently, recent accumulating data suggest that the gut immune system 
plays a role in the development of T1D.  
Administration of Lctb johnsonii N6.2 isolated from BBDR delayed or inhibited the onset of 
T1D in BBDP rats when administered postweaning. Analysis of the intestinal ileum showed 
administration of Lctb johnsonii induced changes in the native microbiota, host mucosal 
proteins, and host oxidative stress response. The administration of Lctb johnsonii also 
resulted in higher levels of the tight junction protein claudin. In this study, low expression 
of pro-inflammatory cytokines IFN-Ǆ correlated with the administration of Lctb johnsonii 
N6.2, whereas low expression of TNF-ǂ correlated with overall healthy status [49]. These 
results indicate that the mechanisms involved in T1D inhibition in BBDP rats may be 
different from the effect mediated by the probiotic treatment VSL#3.  
Previous reports in the NOD model of diabetes have shown that the administration of the 
probiotic formulation VSL#3 decreased the incidence of T1D through IL-10 
immunomodulation and induction of proinflammatory cytokine IFN-Ǆ. Early orally 
administered the probiotic compound VSL#3 induced immunomodulation by a reduction in 
insulitis severity and a decreased rate of ǃ-cell destruction in NOD mice. Prevention was 
associated with an increased production of IL-10 from Peyer's patches and the spleen and 
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with increased IL-10 expression in the pancreas, where IL-10-positive islet-infiltrating 
mononuclear cells were detected [50]. 
Oral feeding of Lctb casei to young NOD mice inhibited the occurrence of T1D, prevented the 
disappearance of insulin-secreting ǃ -cells, and regulated the host immune system response, 
as reflected by lower IFN-Ǆ and higher IL-2 production [51]. From the age of 4 wk, female 
NOD mice were fed a diet containing LcS, and the onset of diabetes was recorded thereafter. 
The incidence of diabetes in the control group was significantly higher than that in the LcS-
treated group, and pathological analysis of the LcS-treated group revealed strong inhibition 
of the disappearance of insulin-secreting ǃ-cells in Langerhans islets. Moreover, the 
proportion of CD8+-T cells among spleen cells was decreased in the LcS treated group, 
suggesting the inhibition of autoreactive T cells. It is postulated that LcS may alter the 
imbalance of Th1/Th2 cytokine production, which is thought to be the cause of the onset of 
T1D [13,51].  
8.4 IIb-probiotic effect in human clinical T1D trials 
The feature of immune-mediated T1D is T cell-mediated destruction of the insulin-
producing ǃ-cell in the islets, which results from an imbalance between disease promoting 
factors and protective elements. The particular mechanisms of ǃ-cell destruction leading to 
diabetes remain still unclear [52]. A pilot study of PRODIA (probiotics for the prevention of 
ǃ-cell autoimmunity in children at genetic risk of T1D) included 200 children with genetic 
risk for T1D. This study was planned to show whether the use of probiotics during the first 
6 months of life is safe and feasible and to determine whether the use of probiotics during 
the first 6 months of life decreases the appearance of T1D-associated autoantibodies. 
However, the prevalence of autoantibodies among the study subjects at 6, 12, and 24 months 
of age was at levels close to the expected and the clinical follow-up did not either indicate 
problems in the feasibility of the study [53]. 
8.5 IIIa-probiotic effect in animal EAE models 
EAE, which is an experimental model for MS, is assumed to be induced by activation of 
autoreactive Th1 cells that recognize myelin basic protein (MBP), which causes 
inflammatory demyelination in the central nervous system. It has been previously 
demonstrated that effects of probiotics on EAE in mice were strain-dependent, either 
stimulating or suppressing the clinical symptoms. In a murine EAE model it was shown that 
the outcome of EAE was dependent upon the cytokine profile induced by different probiotic 
strains. Strains that induced proinflammatory cytokines in the gut aggravated the 
cumulative disease burden, whereas strains that induced regulatory cytokines reduced this 
burden. For instance, LcS and Bfdbm strains induced immunoregulatory cytokines and 
improved EAE, while Lctb reuteri induced proinflammatory cytokines and aggravated EAE 
thru release of Th1-associated cytokines [32]. 
LcS was previously reported to increase the duration of clinical symptoms in a rat EAE model 
[54]. Because experiments involving LcS detected mainly enhancement of innate immune 
responses and promotion of Th1-mediated immune reactivity. To confirm and further 
investigate modulation of Th1 responses and development of AD by LcS, the consequences of 
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oral administration of LcS were assessed in several experiments. And a recent data also 
showing strain-specific differences on the effect of commercially available probiotic drinks in 
an EAE rat has been described. In this particular model, these probiotic drinks do not enhance 
but rather suppress the disease by increasing the production of the regulatory cytokines IL-10 
and TGF-ǃ, which is consistent with the indications that Tregs are involved in EAE [55].  
Furthermore, to evaluate the effects and safety of two probiotic strains, LcS and Bfdbm breve 
strain Yakult (BbY) were orally administered to Lewis rats with EAE. Three experimental 
designs were examined by combining different antigen types and probiotic administration 
periods: (1) EAE was induced with a homogenate of guinea pig spinal cord as the 
sensitizing antigen, and LcS was orally administered from one week before this sensitization 
until the end of the experiment; (2) EAE was induced using guinea pig originated MBP as 
the sensitizing antigen, and LcS was orally administered from one week before this 
sensitization to the end of the experiment; (3) EAE was induced using guinea pig MBP as 
the sensitizing antigen, and the probiotic strains (LcS and BbY) were administered starting 
in infancy (two weeks old) and continued until the end of the experiment. In experiment 1, 
oral administration of LcS tended to suppress the development of neurological symptoms. 
Differences in neurological symptoms between the control group and the administration 
groups did not reach statistical significance in experiments 2 and 3. As a result, these 
findings support the notion that neither LcS nor BbY exacerbates AD [56]. 
Effects of Bfdbm animalis were evaluated during lactation on autoimmune responses in 
rodents. In the EAE model, Bfdbm animalis significantly reduced the duration of clinical 
symptoms and improved the body weight gain compared with the control group. Hence, 
animals that receive Bfdbm animalis recover faster than controls. The mechanisms by which 
Bfdbm animalis induced these beneficial effects on EAE are unclear, but do suggest an 
involvement of Treg cells [57].  
The preventive effects of five daily-administered probiotic mixture strains (two strains of 
Lctb paracasei, two strains of Lctb plantarum and the traditional yogurt bacterium Lctb 
delbrueckii subsp. bulgaricus) were evaluated comparatively on EAE development in mice. 
This novel probiotic mixture exerts a therapeutic effect on EAE mediated by Tregs 
producing IL-10. After a primary screening, three strains, Lctb paracasei DSM 13434, Lctb 
plantarum DSM 15312 and Lctb plantarum DSM 15313, that efficiently prevented EAE 
development were chosen for further evaluation. This new mixture of three probiotics is 
subsequently referred to as ‘‘Lacto-mix’’. The immunosuppressive potential of Lacto-mix 
strains was associated with induction of Tregs and production of IL-4, IL-10 and TGF-ǃ1 in 
mesenteric lymph nodes and spleen. Despite a preventive effect on EAE, administration of 
each individual strain to mice with established EAE was not capable to suppress the disease 
[55]. In another study, treatment with Lacto-mix successfully reversed established EAE and 
demonstrated a unique synergistic effect of these strains to regulate systemic IL-10 release 
and induce functional Tregs in, not only intestinal lymph nodes, but also in the periphery 
and central nervous system of diseased animals [58].  
8.6 IIIb-probiotic effect in human clinical MS trials 
Much of the epidemiological data in MS is consistent with a role for diet in its initiation, 
exacerbations, or progression. Some of the dietary factors contributing to the worsening of 
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MS include a high animal-fat diet; food allergies/intolerances; and digestive malfunctions, 
including malabsorption and dysbiosis. Gut malabsorption and dysbiosis can be corrected 
using probiotics. Although there is no known clinical data on the use of probiotics in MS 
patients, probiotics might have an indirect effect in MS thru correcting dysbiosis [59]. 
8.7 IVa-probiotic effect in animal experimental IBD models 
IBD is a life-long and chronic inflammatory condition of the gastrointestinal tract including 
the 2 major diseases, Crohn’s disease (CD) and UC. A convergence of findings show that 
intestinal microflora play a central role in the pathogenesis of IBD and thus investigators 
have pursued studies to seek therapeutic effects of manipulating intestinal microflora. A 
reduction in microbial burden of gut by public health measures contributes to an 
immunological imbalance in the intestine, which has been explained by the 'hygiene 
hypothesis'. The question is posed to determine whether a similar explanation can be 
proposed for the increased incidence of IBD [9,13-15]. The extension of the hygiene 
hypothesis to IBD opens new therapeutic perspectives including the revisiting of probiotics 
and other forms of exposure to bacteria or parasite components. 
A number of reports have been published that describe the influence of probiotic 
consumption on colitis in animal trials. In particular, the IL-10 -/- (knockout) mouse has been 
extensively studied. IL-10 knockout mice develop colitis when colonized with a 
conventional flora but remain disease-free when maintained under germ-free conditions. 
Schultz et al. colonized IL-10-/- mice with Lctb plantarum 299v two weeks before transfer 
from a germ free environment to a specific pathogen-free environment. This resulted in 
significant attenuation of disease and a significant reduction in mesenteric lymph node IL-12 
and IFN-Ǆ production [60].  
Madsen et al. demonstrated a role for Lctb reuteri in prevention of colitis in IL-10-/- mice. 
Neonatal IL-10-/- mice were shown to have a decreased concentration of colonic Lctb species 
and an increased concentration of mucosal adherent bacteria. Oral administration of the 
prebiotic lactulose (shown to increase the levels of Lctb species) and rectal swabbing with 
Lctb reuteri restored Lctb levels to normal and reduced the number of adherent bacteria 
within the colon. These effects were associated with the attenuation of colitis [61].   
In another placebo-controlled trial the efficacy of Lctb salivarius UCC118 and Bfdbm infantis 
35624 in attenuation of colitis in the IL-10-/- mouse model was demonstrated. Further studies 
examined the effect of Bfdbm infantis 35624 on early inflammation in IL-10-/- mice and wild-
type mice of the same genetic background. Pronounced changes occurred in the Peyer’s 
patch following probiotic consumption, with IFN-Ǆ reduced in both wild-type and IL-10-/- 
mice [62].  
The oral route of administration may not be required for certain probiotic effects. Reduced 
inflammatory scores and reduced production of proinflammatory cytokines have been 
observed in IL-10-/- mice that had been injected subcutaneously with Lctb salivarius 
UCC118 [63]. Additionally; in order to enhance the probiotic effect in these murine models, 
investigators have combined probiotic treatment with prebiotics, antibiotics, 
immunostimulatory DNA sequences or they have genetically engineered the probiotic strain 
to secrete antiinflammatory mediators. The prebiotic inulin and a combination of the 
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probiotic organisms Lctb acidophilus La-5, Lctb delbruckii subsp. bulgaricus, Bfdbm Bb-12, 
and Streptococcus thermophilus significantly reduced inflammation [64]. The effect was 
enhanced by combination with metronidazole, suggesting a synergistic effect of the 
combination of anti- and probiotics in the treatment of experimental colitis [65]. Attenuation 
of DSS (dextran sulfate sodium) colitis was caused by VSL#3 DNA mediated through TLR- 9 
signaling. Isolated DNA of E. coli strain Nissle 1917 showed an antiinflammatory effect in the 
DSS model as well. Interestingly, specific immunostimulatory DNA sequences have also 
been shown to attenuate the production of proinflammatory cytokines in UC patients [66]. 
Genetically modified probiotics have been tested for their ability to attenuate colitis in the 
IL-10 knockout model. Lactococcus lactis was engineered to secrete biologically active IL-10. 
A significant reduction in inflammation was observed in both murine models [67].  
8.8 IVb-probiotic effect in human clinical IBD trials 
Studies on the use of probiotics in the treatment of noninfectious inflammatory bowel 
disorders found that 4 strains of Lctb and 1 strain of Streptococcus were effective in 
maintaining remission of UC and reducing the postop recurrence of CD. In the randomized 
controlled trials, 12 of 16 UC but only 2 of CD trials of probiotic therapy were successful. No 
superiority of any probiotic was clearly evident, but a multi-agent mixture, VSL3# may be 
better suited in UC and pouchitis [68]. And studies of probiotics e.g. LGG in CD have been 
disappointing, and a recent Cochrane systematic review has concluded that their use could 
not be recommended on the available evidence [69].  
9. Pouchitis 
The most compelling evidence for the use of probiotics in IBD comes from randomised 
double-blind placebo controlled trials with VSL#3 (a mixture of four species of lactobacilli, 
three species of bifidobacteria and Streptococcus thermophilus) in patients with pouchitis. 
The efficacy of VSL#3 as a maintenance treatment in 40 patients with chronic relapsing 
pouchitis after antibiotic-induced remission was assessed. After 4 months fewer relapses 
were found to occur in the intervention group than in the control group. Moreover, all 
patients were subsequently found to relapse 3 months after cessation of VSL#3. Later, the 
same group assessed VSL#3 in the primary prevention of pouchitis in 40 patients following 
surgery. The incidence of pouchitis was found to be reduced and the quality of life 
improved in the VSL#3-treated group compared with the placebo group [68]. Finally, a 
further study has confirmed the effectiveness of VSL#3 as maintenance therapy in patients 
with recurrent or chronic pouchitis [70]. In contrast, Shen et al. have reported no significant 
benefit of VSL#3 in maintaining antibiotic-induced remission in 31 patients [71].  
Trials of other probiotics in the management of pouchitis have yielded mixed results. One 
observational study of patients receiving LGG after pouch formation has reported a lower 
rate of pouchitis than in historical controls [72]. However, Kuisma et al. have found no 
difference in mean pouchitis scores between placebo and LGG-treated groups at the end of a 
3-month study period [73]. Finally, a reduction in endoscopic and clinical disease activity 
associated with an increase in faecal probiotic species has been demonstrated in 51 patients 
with pouchitis after surgery for UC who consumed fermented milk containing lactobacilli 
and bifidobacteria [74]. 
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10. UC 
10.1 Probiotics to treat active UC 
In a study comparing the effect of probiotic E. coli Nissle 1917 vs. mesalamine on induction 
of remission in UC, both groups had similar time to remission, demonstrating equal efficacy 
of treatments. Consistently, several controlled trials have demonstrated that E. coli Nissle 
1917 has similar efficacy to conventional mesalazine treatment with fewer side effects [75]. 
Efficacy of direct delivery of the probiotic to the colon with E. coli Nissle 1917 enemas in 
left-sided UC has been demonstrated [76].  
In an open-label trial, VSL#3 was added to current regimen for patients who had failed to 
respond to conventional therapy for active UC. Addition of VSL#3 for 6 weeks led to either 
remission or response in 77% of patients as measured by the disease activity index [68].  
Active UC was treated with fermented milk including BbY, Bfdbm bifidum strain Yakult 
and an Lctb acidophillus strain [77]. A recent clinical trial demonstrated that treatment of 
patients with Bfdbm fermented milk compared to placebo leads to a significant decrease in a 
clinical activity index score, as well as a significant decrease in endoscopic and histological 
scores after 12 weeks of treatment [78]. 
10.2 Probiotics as maintenance therapy in UC 
Treatment with VSL#3 to maintain remission in UC was found to be only 4 of 20 patients 
had experienced relapse at the end of the study [79]. Several studies examining the use of 
lactobacilli or bifidobacteria as maintenance treatment in UC have demonstrated conflicting 
results. Ishikawa et al. have demonstrated a reduction in the number of disease 
exacerbations in a group of Japanese patients receiving fermented milk containing Bfdbm 
breve, Bfdbm bifidum and Lctb acidophilus compared with placebo. However, this clinical 
benefit was not found to be associated with an increase in steroid-free remission or 
endoscopic improvement in disease activity [78]. Another open-label trial showed that for 
maintenance of remission in UC that LGG alone, or in combination with mesalamine, 
demonstrated equal efficacy to mesalamine alone [76,80].  
11. CD 
11.1 Probiotics to treat active CD  
Previous two studies with E. coli Nissle 1917 and LGG had evaluated probiotics in active CD 
patients, but neither study has demonstrated convincing efficacy, in part because of small 
numbers of patients [81]. A recent double-blinded placebo controlled trial randomized 11 
patients with active CD to receive either LGG or placebo. There was no difference in at the 
rate of inducing remission for 6 months between the two groups [82]. 
11.2 Probiotics to maintain remission in CD 
Evidence for use of probiotics as maintenance therapy in CD is not persuasive, with only a 
couple of studies reporting positive results. A study comparing S. 
boulardii+antibiotic+mesalazine with mesalazine alone has shown fewer relapses in the 
former group in patients with medically-induced remission of CD [83]. A recent double-
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blinded placebo controlled trial randomized 11 patients with active CD to receive either 
LGG or placebo. There was no difference at the rate of sustaining remission for 6 months 
between the two groups [82]. Another randomized, double blind study compared LGG vs. 
placebo in addition to standard maintenance therapy in a group of 75 children. These 
studies did not find any advantage for LGG compared with placebo in maintaining 
medically-induced remission [84].  
Several clinical studies have been performed to analyze the effects of probiotics on 
maintaining surgically-induced remission. Three studies using LGG have not confirmed the 
effectiveness of this probiotic as a maintenance strategy after surgically-induced remission 
[84,85]. Another clinical trial utilizing treatment with LGG after surgical resection failed to 
show prevention of early endoscopic recurrence when compared to placebo. One study 
suggested modest but not significant improvement in recurrence rates of patients after 
surgical resection of diseased bowel by Lctb johnsonii LA1 [86]. However, two randomised 
double-blind placebo-controlled studies have reported no effect of Lctb. johnsonii LA1 in 
preventing recurrence in CD patients in surgically induced remission [86,87]. Lastly; 
Campieri et al. have shown benefit of VSL#3 in preventing post-operative recurrence in 40 
patients randomised to 3 months of rifaximin followed by 9 months of VSL#3 or to 12 
months of mesalazine [88]. 
12. Celiac disease  
The only effective treatment for Celiac is a strict adherence to a gluten-free diet throughout 
the patient's lifetime. Otherwise, wheat gliadin induces severe intestinal symptoms and 
small-bowel mucosal damage in patients. Gluten-free products are not widely available and 
are usually more expensive than their gluten-containing counterparts. There is, therefore, an 
urgent need to develop safe and effective therapeutic alternatives, to develop high-quality 
gluten-free products and to investigate the potential of the bread making biotechnology 
following ancient protocols, which include long-time fermentation by selected sourdough 
LAB. There is a necessity for new biotechnologies using probiotics as starters for sourdough 
fermentation to investigate their potential to decrease the risk of gluten contamination in 
gluten-free products.  
Thus, 46 strains of sourdough LAB were screened for proteolytic activity and acidification 
rate in gluten-free flours. The sourdough cultures consisted of Lctb sanfranciscensis and 
plantarum were selected and used for the manufacture of gluten-free bread [89]. Moreover, 
proteolytic activity by probiotic VSL#3 was also found to have an importance during food 
processing to produce predigested and tolerated gliadins for increasing the palatability of 
gluten-free products [90]. In addition; Bfdbm lactis was found to inhibit the toxic effects of 
gliadin in intestinal cell culture conditions [91].  
13. Conflicting results and reasons of failure in human AD clinical trials 
Although human clinical trials for therapeutic probiotic use in AD have been somewhat 
disappointing, human trials are also performed unsatisfactorily. Firstly, one of the main 
reasons for this failure is that the topic is becoming currently popular and further studies 
need to be done. For instance: although arthritis trials both in human and animal are partly 
successful, there is no still enough clinical data on the use of probiotics in MS and T1D 
patients.  
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Secondly; since human is a more complex organism than cell cultures and animals, 
performing a research in human is very difficult. As expected, most of the hopeful data 
firstly have come from in vitro cell culture studies and experimental animal models. 
Thirdly, there are also difficulties of recognizing mechanisms implicated in ADs. As 
mentioned upper part of this review; there at least several hypotheses for autoimmunity 
development and there a lot need to be further clarified. Thus, it is very difficult to decide 
what kind of probiotic strain would be helpful.  
Fourthly, it is very hard to measure net effect of probiotic since the effect of probiotic use is 
specifically dependent upon strain. Consequently, there is also a large amount of conflicting 
data on the probiotic use in ADs. 
Fifthly, there is also fear from possible side effects of probiotics. As mentioned above, the 
fact that certain probiotics are known to stimulate Th1 immunity, which might be an 
additional safety issue. Excessive immunostimulation might aggravate or induce Th1-
mediated immune responses, e.g. ADs.  
14. Expert commentary (Conclusion) 
As mentioned above, there is a large amount of conflicting data on the 
preventive/therapeutic effects of probiotics in ADs. Results from metaanalyses and 
systematic reviews that combine results of studies from different types of probiotics to 
examine the effects in any disease should be interpreted with caution. There are also 
difficulties of recognizing etiology and pathogenesis of ADs from RA to IBD in which have 
many mechanisms involved. Similarly, with various strains, especially LcS, stimulation of 
Th1-mediated immune responses has been described. Additionally, if probiotics are used in 
patients with ADs for any reason –therapy or prevention- cautionary approach ought to be 
taken. Thus, probiotics cannot be recommended generally for primary prevention of ADs. 
Any probiotics should not be used especially in immune-compromised children; even they 
have at risk for ADs. Finally, there is insufficient but fairly promising evidence to 
recommend the addition of probiotics to foods for prevention and treatment of ADs.  
14.1 Five-year view 
Involvement of commensal enteric microflora and its components with strong 
immunoactivating properties in etiopathogenetic mechanism of multifactorial diseases, 
including IBD, T1D, RA, and allergy has been recently suggested. Regulation of intestinal 
microflora composition (e.g. by probiotics) offers the possibility to influence the 
development of mucosal and systemic immunity as well as it can play a role also in 
prevention and treatment of some ADs. Progress has been made by the identification of 
receptors and pathways through which gut microbes influence development of the immune 
system. Such mechanistic data have moved a field that was once regarded as being on the 
scientific fringe to the mainstream, and support increased funding to advance this 
promising area of research in the hope that it might deliver the long awaited answer of how 
to safely prevent ADs. 
Better understanding of the effects of different probiotic strains and a deeper insight into the 
mechanisms of the heterogeneous manifestations of AD are needed for the validation of 
specific strains carrying anti-autoimmune potential. Therefore, research activities are 
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currently focusing on identification of specific probiotic strains with immunomodulatory 
potential and on how dietary content interacts with the most efficacious probiotic strains. 
Moreover, the selection of the most beneficial probiotic strain, the dose, and the timing of 
supplementation still need to be determined. Further studies should also clarify if any 
susceptible groups of ADs exist and how these groups benefit from supplementation with 
certain probiotic strains.  
Some studies in the management of ADs suggest that therapeutic benefit requires a 
combination of probiotic species (as with VSL#3 or Lacto-mix) or that the component(s) 
responsible for the anti-inflammatory effect in combination preparations have specific 
properties that monotherapy probiotics do not. This concept also supports the use of 
prebiotics that increase concentrations of several commensal immunoregulatory bacteria. 
Prebiotic use was shown to be associated with a reduction in the faecal concentration of 
Bacteroides fragilis, but had no effect on lactobacilli or bifidobacteria. Genetically modified 
probiotics will be tested for their ability to attenuate ADs thru secreting regulatory cytokines 
in experimental models as well. In near future, the researchers will look for more 
appropriate combinations of probiotic species or modified probiotics with/without prebiotic 
and test them in human/rodent AD models.  
Additionally, side effects are very low and they might not be nonexistent, as shown in a set 
of patients with different diseases. However, probiotics should not be considered as totally 
harmless, particularly in the immunodeficient host, and more safety studies are needed. As 
imagined, probiotics may have unpredictable behaviour like all microorganisms, such as 
unanticipated gene expression in nonnative host environment, or acquired mutations 
occurring spontaneously via bacterial DNA-transfer mechanisms. Certain probiotics are 
known to stimulate Th1 immunity, which has been suggested as one of the mechanisms by 
which they can suppress Th2-mediated allergic diseases. However, this presumed excessive 
immunostimulation might aggravate or induce Th1-mediated immune responses and 
diseases such as T1D, MS; and it might cause an additional safety issue. 
Consequence of over-activation of the immune system by probiotics in hosts with immune 
dysfunctions, such as individuals genetically predisposed to autoimmunity, has raised some 
concerns too. With respect to the association between bacterial antigens and autoimmune 
responses and the adjuvant activity of LAB strains, the involvement of LAB in the 
pathogenesis of some models of autoimmunity in experimental animals and possibly in 
humans has been suggested. Thus, from a safety point of view, the potential of probiotic 
bacteria (especially the immunostimulatory strains), to induce destructive inflammation or 
autoimmunity needs to be investigated. For instance, it has been experimentally 
demonstrated that Lctb casei cell wall components (given intraperitoneally) are able to 
induce cardioangitis (an autoimmunity-associated heart disease) in mice [92]. 
14.2 Key issues  
 Since conclusions on probiotics are limited to specific strains and models, they should 
not be generalized [32,54,55]. 
 Probiotics should not be considered as completely harmless, particularly in the 
immunodeficient host, and more safety studies are needed [54,92]. 
 Physiological use (normal route, normal dose, normal growth phase, specific strain or 
substrain/species) is studied in all cases, so as not to overwhelm (high dose) or 
circumvent natural immune processing [54,92]. 
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 Do probiotics really induce/exacerbate ADs? LGG and others have specific dose- and 
duration- dependent immunomodulatory effects on the proliferation of B-/T-
lymphocytes. Some mice orally fed lactobacilli were demonstrated to have an increased 
Th1 cytokine production. And this type of immunomodulatory mechanism might 
exacerbate Th1-dependent ADs [32,54,55,92]. 
 Th1-mediated immune response stimulation also seems to be dependent on type of 
disease model as well as probiotic strain. In SJL mice with EAE showed that different 
lactobacilli strains could enhance or inhibit development of ADs [32,54]. And some 
immunostimulatory probiotics do not always seem to induce autoimmune responses in 
models that have the genetic potential to develop autoimmunity. Such as Lctb 
rhamnosus HN001 and Bfdbm lactis HN019 do not induce pathological inflammation in 
mouse model of experimental autoimmune thyroiditis [93].  
 The researchers ought to look for more appropriate and safe combinations of probiotic 
species (as with VSL#3 or Lacto-mix) or modified probiotics with/without prebiotic 
and test them in human/rodent AD models [55]. 
 Research activities are currently focusing on identification of specific probiotic strains 
with immunomodulatory potential and on how dietary content interacts with the most 
efficacious probiotic strains. Further studies should be made for the identification of 
receptors and pathways through which gut microbes influence development of the 
immune system. 
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